Ken Griffin Grifols Sa Transaction History

Citadel Advisors LLC

$509 Billion
Q1 2025

A detailed history of Ken Griffin (Citadel Advisors LLC) transactions in Grifols Sa stock. As of the latest transaction made, Citadel Advisors LLC holds 2,600 shares of GRFS stock, worth $20,176. This represents 0.0% of its overall portfolio holdings.

Number of Shares

2,600

Previous 3,700 29.73%

Holding current value

$20,176

Previous $27,000 33.33%

% of portfolio

0.0%

Previous 0.0%

30 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2025 May 15, 2025	BUY	$6.62 - $8.71 $135,518 - $178,302	20,471 Added 33.02%	82,472 $586,000
Q4 2024 Feb 14, 2025	SELL	$6.99 - $9.55 $1.43 Million - $1.96 Million	-205,233 Reduced 76.8%	62,001 $461,000
Q3 2024 Nov 14, 2024	BUY	$6.28 - $9.38 $1.12 Million - $1.67 Million	178,220 Added 200.22%	267,234 $2.37 Million
Q2 2024 Aug 14, 2024	SELL	$6.27 - $7.7 $264,669 - $325,032	-42,212 Reduced 32.17%	89,014 $560,000
Q1 2024 May 15, 2024	SELL	$5.47 - $11.38 $957,064 - $1.99 Million	-174,966 Reduced 57.14%	131,226 $876,000
Q4 2023 Feb 14, 2024	BUY	$7.71 - $11.56 $2.02 Million - $3.03 Million	262,463 Added 600.2%	306,192 $3.54 Million
Q3 2023 Nov 14, 2023	BUY	$8.91 - $10.91 $84,030 - $102,892	9,431 Added 27.5%	43,729 $399,000
Q2 2023 Aug 14, 2023	BUY	$7.14 - $9.29 $186,810 - $243,063	26,164 Added 321.66%	34,298 $314,000
Q1 2023 May 15, 2023	SELL	$6.65 - $10.69 $1.78 Million - $2.86 Million	-267,785 Reduced 97.05%	8,134 $59,000
Q4 2022 Feb 14, 2023	SELL	$5.96 - $8.53 $5.3 Million - $7.59 Million	-889,501 Reduced 76.32%	275,919 $2.35 Million
Q3 2022 Nov 14, 2022	BUY	$5.95 - $14.3 $5.96 Million - $14.3 Million	1,000,998 Added 608.8%	1,165,420 $7.18 Million
Q2 2022 Aug 15, 2022	SELL	$10.6 - $13.28 $2.7 Million - $3.38 Million	-254,615 Reduced 60.76%	164,422 $1.95 Million
Q1 2022 May 16, 2022	BUY	$10.37 - $12.73 $36,460 - $44,758	3,516 Added 0.85%	419,037 $4.89 Million
Q4 2021 Feb 14, 2022	BUY	$10.21 - $15.27 $3.42 Million - $5.12 Million	335,141 Added 416.95%	415,521 $4.67 Million
Q3 2021 Nov 15, 2021	SELL	$14.07 - $17.3 $1.89 Million - $2.32 Million	-134,202 Reduced 62.54%	80,380 $1.17 Million
Q2 2021 Aug 16, 2021	BUY	$16.62 - $18.94 $778,464 - $887,130	46,839 Added 27.92%	214,582 $3.72 Million
Q1 2021 May 17, 2021	BUY	$15.15 - $19.78 $1.08 Million - $1.41 Million	71,516 Added 74.32%	167,743 $2.9 Million
Q4 2020 Feb 16, 2021	SELL	$16.86 - $19.67 $3.93 Million - $4.59 Million	-233,099 Reduced 70.78%	96,227 $1.77 Million
Q3 2020 Nov 16, 2020	BUY	$15.4 - $20.16 $3.18 Million - $4.16 Million	206,483 Added 168.09%	329,326 $5.71 Million
Q2 2020 Aug 14, 2020	BUY	$18.24 - $21.45 $2.24 Million - $2.63 Million	122,843 New	122,843 $2.24 Million
Q1 2020 May 15, 2020	SELL	$16.28 - $25.63 $573,365 - $902,662	-35,219 Closed	0 $0
Q4 2019 Feb 14, 2020	SELL	$19.57 - $23.52 $28.7 Million - $34.5 Million	-1,466,862 Reduced 97.66%	35,219 $821,000
Q3 2019 Nov 14, 2019	BUY	$19.85 - $22.76 $15.7 Million - $18 Million	791,621 Added 111.42%	1,502,081 $30.1 Million
Q2 2019 Aug 14, 2019	BUY	$17.59 - $21.1 $3.68 Million - $4.42 Million	209,278 Added 41.76%	710,460 $15 Million
Q1 2019 May 15, 2019	BUY	$18.01 - $20.11 $6.53 Million - $7.29 Million	362,451 Added 261.26%	501,182 $0
Q4 2018 Feb 14, 2019	BUY	$17.44 - $21.53 $1.77 Million - $2.19 Million	101,775 Added 275.4%	138,731 $2.55 Million
Q2 2018 Aug 10, 2018	BUY	$20.16 - $24.68 $745,032 - $912,074	36,956 New	36,956 $0
Q1 2018 May 11, 2018	SELL	$20.31 - $24.95 $1.81 Million - $2.23 Million	-89,273 Closed	0 $0
Q4 2017 Feb 09, 2018	SELL	$20.99 - $23.89 $2.2 Million - $2.5 Million	-104,654 Reduced 53.97%	89,273 $2.05 Million
Q3 2017 Nov 09, 2017	BUY	$20.07 - $21.89 $3.89 Million - $4.25 Million	193,927	193,927 $4.25 Million

Others Institutions Holding GRFS

# of Institutions

166

Shares Held

153M

Call Options Held

76.5K

Put Options Held

106K

View Full List

About Grifols SA

Ticker GRFS
Exchange OTC
Sector Healthcare
Industry Drug Manufacturers—General
Shares Outstandng 678,910,976
Market Cap $5.27B
Description
Grifols, S.A. engages in the procurement, manufacture, preparation, and sale of therapeutic products, primarily hemoderivatives. The company operates through Bioscience, Hospital, Diagnostic, Bio Supplies, and Others divisions. The Bioscience division researches, develops, produces, and markets plasma-derived medicines and other innovative solut...

More about GRFS

Track Ken Griffin's Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

News

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.

Account